Nintedanib

Summary

Nintedanib (CHEMBL502835) is an approved small-molecule antineoplastic agent (ATC L01EX09) targeting LATS1, PDGFRA, and PDGFRB; indicated across 50 conditions including neoplasm and systemic sclerosis; with CIViC clinical evidence for 1 variant-indication association (e.g. CCDC6::RET Fusion in lung non-small cell carcinoma).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: L01EX09
• Targets: 10 (LATS1, PDGFRA, PDGFRB…)
• Indications: 50 conditions
• Clinical trials: 157
• Precision-oncology evidence (CIViC): 1 variant–indication association
• Chemistry: C31H33N5O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL502835
Name	Nintedanib
Type	Small molecule
Max phase	4
ChEBI	CHEBI:85164
ATC	L01EX09
Molecular formula	C31H33N5O4
InChIKey	XZXHXSATPCNXJR-ZIADKAODSA-N

SMILES: COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1

ChEBI definition: A member of the class of oxindoles that is a kinase inhibitor used (in the form of its ethylsulfonate salt) for the treatment of idiopathic pulmonary fibrosis and cancer.

Pharmacological roles (ChEBI): antineoplastic agent, tyrosine kinase inhibitor, vascular endothelial growth factor receptor antagonist, fibroblast growth factor receptor antagonist, angiogenesis inhibitor, antifibrotic agent.

Also known as: BIBF 1120, Bibf-1120, BIBF-1120, BIBF1120, Intedanib, Nintedanib, Nintedanib component of ofev, Ofev, Vargatef, NINTEDANIB, NINTEDANIB (BIBF 1120), Nintedanib (BIBF 1120)

Parent form; salt/anhydrous children: CHEMBL3039504

Patent coverage: 3,489 distinct patent families (8,545 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 8,171 (96%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
LATS1	large tumor suppressor kinase 1	Inhibition	4.97	0.1%	O95835
PDGFRA	platelet derived growth factor receptor alpha	Inhibition	7.23	6.2%	P16234
PDGFRB	platelet derived growth factor receptor beta	Inhibition	7.19	2.3%	P09619
FGFR1	fibroblast growth factor receptor 1	Inhibition	7.16	11.5%	P11362
FGFR2	fibroblast growth factor receptor 2	Inhibition	7.43	1.7%	P21802
FGFR3	fibroblast growth factor receptor 3	Inhibition	6.97	0.5%	P22607
FGFR4	fibroblast growth factor receptor 4	Inhibition	6.21	0.7%	P22455
FLT1	fms related receptor tyrosine kinase 1	Inhibition	7.51	0.1%	P17948
KDR	kinase insert domain receptor	Inhibition	7.68	1.1%	P35968
FLT4	fms related receptor tyrosine kinase 4	Inhibition	7.89	0.2%	P35916

Broader ChEMBL bioactivity targets: 232 (assay-derived). Sample: Leucine-rich repeat serine/threonine-protein kinase 2, Rhodopsin kinase GRK7, Homeodomain-interacting protein kinase 4, Serine/threonine-protein kinase/endoribonuclease IRE1, Serine/threonine-protein kinase OSR1, STE20/SPS1-related proline-alanine-rich protein kinase, Mitogen-activated protein kinase kinase kinase 13, Serine/threonine-protein kinase ICK, Mitogen-activated protein kinase kinase kinase 15, Microtubule-associated serine/threonine-protein kinase 1.

Bioactivity

ChEMBL activities: 408 potent at pChembl ≥ 5 of 414 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
FLT3	9.38	Kd	0.42	nM	CHEMBL_ACT_7574800
FLT3	9.15	Kd	0.71	nM	CHEMBL_ACT_7574799
FLT3	9.15	Kd	0.7	nM	CHEMBL_ACT_7574801
KDR	8.98	IC50	1.05	nM	CHEMBL_ACT_29116554
PDGFRB	8.74	IC50	1.8	nM	CHEMBL_ACT_18330886
PDGFRB	8.74	IC50	1.8	nM	CHEMBL_ACT_25952266
MAP2K5	8.74	Kd	1.8	nM	CHEMBL_ACT_7575034
PDGFRA	8.72	IC50	1.9	nM	CHEMBL_ACT_17957990
PDGFRB	8.7	IC50	2	nM	CHEMBL_ACT_13392443
BMP2K	8.66	Kd	2.2	nM	CHEMBL_ACT_7574975
PDGFRA	8.64	IC50	2.3	nM	CHEMBL_ACT_18314194
KCNH2	8.59	IC50	2.6	nM	CHEMBL_ACT_18330841
FLT3	8.59	Kd	2.6	nM	CHEMBL_ACT_7574803
KIT	8.57	Kd	2.7	nM	CHEMBL_ACT_7573114
KIT	8.54	Kd	2.9	nM	CHEMBL_ACT_7573116
KDR	8.54	Kd	2.9	nM	CHEMBL_ACT_7573185
RET	8.52	Kd	3	nM	CHEMBL_ACT_17935250
FLT4	8.52	IC50	3	nM	CHEMBL_ACT_17957988
KDR	8.51	IC50	3.1	nM	CHEMBL_ACT_18330868
KDR	8.51	IC50	3.1	nM	CHEMBL_ACT_25952267
FLT4	8.49	IC50	3.2	nM	CHEMBL_ACT_18314196
KDR	8.48	IC50	3.3	nM	CHEMBL_ACT_17957957
PDGFRB	8.46	IC50	3.5	nM	CHEMBL_ACT_18314118
P9WI81	8.44	Kd	3.6	nM	CHEMBL_ACT_7575018
PDGFRB	8.43	IC50	3.7	nM	CHEMBL_ACT_17957974
FLT3	8.42	Kd	3.8	nM	CHEMBL_ACT_13475365
PDGFRB	8.42	IC50	3.8	nM	CHEMBL_ACT_20681243
KDR	8.42	Ki	3.8	nM	CHEMBL_ACT_27981029
KDR	8.42	Ki	3.8	nM	CHEMBL_ACT_28409693
KDR	8.42	Ki	3.8	nM	CHEMBL_ACT_28576667

Target pathways

Aggregated over 10 target gene(s): LATS1, PDGFRA, PDGFRB, FGFR1, FGFR2, FGFR3, FGFR4, FLT1, KDR, FLT4.

Top Reactome pathways

74 total, by targets touching each:

Pathway	Targets	Genes
PIP3 activates AKT signaling	6	FGFR1, FGFR2, FGFR3, FGFR4, PDGFRA, PDGFRB
Constitutive Signaling by Aberrant PI3K in Cancer	6	FGFR1, FGFR2, FGFR3, FGFR4, PDGFRA, PDGFRB
RAF/MAP kinase cascade	6	FGFR1, FGFR2, FGFR3, FGFR4, PDGFRA, PDGFRB
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	6	FGFR1, FGFR2, FGFR3, FGFR4, PDGFRA, PDGFRB
PI3K Cascade	4	FGFR1, FGFR2, FGFR3, FGFR4
VEGF binds to VEGFR leading to receptor dimerization	3	FLT1, FLT4, KDR
Downstream signal transduction	2	PDGFRA, PDGFRB
Signaling by PDGF	2	PDGFRA, PDGFRB
Neuropilin interactions with VEGF and VEGFR	2	FLT1, KDR
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells	2	FLT4, KDR
betaKlotho-mediated ligand binding	1	FGFR4
Signal Transduction	1	LATS1
Signaling by FGFR1 amplification mutants	1	FGFR1
Signaling by activated point mutants of FGFR1	1	FGFR1
FGFR4 mutant receptor activation	1	FGFR4
Signaling by activated point mutants of FGFR3	1	FGFR3
FGFR4 ligand binding and activation	1	FGFR4
FGFR1b ligand binding and activation	1	FGFR1
FGFR3b ligand binding and activation	1	FGFR3
FGFR3c ligand binding and activation	1	FGFR3
FGFR1c ligand binding and activation	1	FGFR1
FGFR1c and Klotho ligand binding and activation	1	FGFR1
FGFR2c ligand binding and activation	1	FGFR2
FGFR2b ligand binding and activation	1	FGFR2
Signaling by FGFR2 amplification mutants	1	FGFR2
Signaling by Hippo	1	LATS1
t(4;14) translocations of FGFR3	1	FGFR3
Activated point mutants of FGFR2	1	FGFR2
Integrin cell surface interactions	1	KDR
NCAM signaling for neurite out-growth	1	FGFR1

Dominant GO biological processes

GO term	Targets
protein phosphorylation	10
positive regulation of cell population proliferation	9
peptidyl-tyrosine phosphorylation	8
protein autophosphorylation	8
cell migration	7
positive regulation of ERK1 and ERK2 cascade	7
positive regulation of MAPK cascade	7
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	6
angiogenesis	6
cell surface receptor protein tyrosine kinase signaling pathway	5
positive regulation of cell migration	5
lung development	4
skeletal system morphogenesis	4
fibroblast growth factor receptor signaling pathway	4
in utero embryonic development	3

Indications & clinical

Indications

50 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neoplasm	3	MONDO:0005070	EFO:0000616
systemic sclerosis	3	MONDO:0005100	EFO:0000717
idiopathic pulmonary fibrosis	3	MONDO:0800504	EFO:0000768
non-small cell lung carcinoma	3	MONDO:0005233	EFO:0003060
colorectal neoplasm	3	MONDO:0005335	EFO:0004142
interstitial lung disease	3	MONDO:0015925	EFO:0004244
pulmonary fibrosis	3	MONDO:0002771	EFO:0009448
severe acute respiratory syndrome	3	MONDO:0005091	MONDO:0100096
colorectal adenocarcinoma	3	MONDO:0005008	EFO:0000365
renal cell carcinoma	2	MONDO:0005086	EFO:0000681
hepatocellular carcinoma	2	MONDO:0007256	EFO:0000182
acute myeloid leukemia	2	MONDO:0018874	EFO:0000222
small cell lung carcinoma	2	MONDO:0008433	EFO:0000702
cervical adenocarcinoma	2	MONDO:0005153	EFO:0001416
mesothelioma	2	MONDO:0005065	EFO:0000588
sarcoma	2	MONDO:0005089	EFO:0000691
malignant pleural mesothelioma	2	MONDO:0005112	EFO:0000770
gastric adenocarcinoma	2	MONDO:0005036	EFO:0000503
prostate adenocarcinoma	2	MONDO:0005082	EFO:0000673
glioblastoma	2	MONDO:0018177	EFO:0000519
squamous cell lung carcinoma	2	MONDO:0005097	EFO:0000708
anaplastic astrocytoma	2	MONDO:0016684	EFO:0002499
anaplastic oligodendroglioma	2	MONDO:0016696	EFO:0002501
ovarian neoplasm	2	MONDO:0021068	EFO:0003893
upper aerodigestive tract neoplasm	2	MONDO:0005398	EFO:0004284
gliosarcoma	2	MONDO:0016681	EFO:1001465
bronchiolitis obliterans syndrome	2	MONDO:0015265	EFO:0007183
urothelial carcinoma	2	MONDO:0040679	EFO:0008528
carcinoid tumor	2	MONDO:0005369	EFO:0004243
appendiceal neoplasm	2	MONDO:0001236	MONDO:0001235
peritoneal neoplasm	2	MONDO:0006901	MONDO:0002087
fallopian tube neoplasm	2	MONDO:0021092	MONDO:0002158
salivary gland cancer	2	MONDO:0004669	MONDO:0004669
breast neoplasm	2	MONDO:0021100	MONDO:0007254
ovarian cancer	2	MONDO:0008170	MONDO:0008170
lung neoplasm	2	MONDO:0021117	MONDO:0008903
endometrium neoplasm	2	MONDO:0021251	MONDO:0011962
lymphangioleiomyomatosis	2	MONDO:0011705	MONDO:0011705
hereditary hemorrhagic telangiectasia	2	MONDO:0019180	MONDO:0019180
neuroendocrine neoplasm	2	MONDO:0019496	EFO:1001901
plasma cell myeloma	1	MONDO:0009693	EFO:0001378
exocrine pancreatic carcinoma	1	MONDO:0005192	EFO:0002618
cutaneous melanoma	1	MONDO:0005012	EFO:0000389
female reproductive organ cancer	1	MONDO:0001416	EFO:1001331
lung adenocarcinoma	1	MONDO:0005061	EFO:0000571
colon adenocarcinoma	1	MONDO:0002271	EFO:1001949
rectal neoplasm	1	MONDO:0002165	MONDO:0044937
colonic neoplasm	1	MONDO:0005401	MONDO:0021063

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 157.

Phase distribution

Phase	Trials
PHASE2	48
PHASE1	45
Not specified	24
PHASE3	21
PHASE4	11
PHASE1/PHASE2	7
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06479603	PHASE4	RECRUITING	RCT of Nintedanib in Fibrotic Sarcoidosis
NCT07485920	PHASE4	NOT_YET_RECRUITING	A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer
NCT02579603	PHASE4	COMPLETED	Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF
NCT02598193	PHASE4	COMPLETED	Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF)
NCT02606877	PHASE4	COMPLETED	A Study to Compare the Amount of Nintedanib and Pirfenidone in the Blood When Nintedanib and Pirfenidone Are Given Separately or in Combination
NCT02788474	PHASE4	COMPLETED	Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment
NCT03717012	PHASE4	TERMINATED	Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT03939520	PHASE4	COMPLETED	Management of Progressive Disease in Idiopathic Pulmonary Fibrosis
NCT04619680	PHASE4	COMPLETED	The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19
NCT04856111	PHASE4	UNKNOWN	Pirfenidone vs. Nintedanib for Fibrotic Lung Disease After Coronavirus Disease-19 Pneumonia
NCT05799755	PHASE4	COMPLETED	Myositis Interstitial Lung Disease Nintedanib Trial
NCT06297096	PHASE3	RECRUITING	Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease
NCT07162961	PHASE3	NOT_YET_RECRUITING	Nintedanib for Improving Reproductive Outcomes in Adenomyosis
NCT07335562	PHASE3	RECRUITING	A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
NCT00806819	PHASE3	COMPLETED	Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
NCT01015118	PHASE3	COMPLETED	LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer
NCT01335464	PHASE3	COMPLETED	Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
NCT01335477	PHASE3	COMPLETED	Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
NCT01619085	PHASE3	COMPLETED	Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
NCT01907100	PHASE2/PHASE3	TERMINATED	Nintedanib (BIBF 1120) in Mesothelioma
NCT01979952	PHASE3	COMPLETED	Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
NCT02149108	PHASE3	COMPLETED	Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)
NCT02231164	PHASE3	TERMINATED	LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research
NCT02597933	PHASE3	COMPLETED	A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis
NCT02802345	PHASE3	COMPLETED	Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment
NCT02999178	PHASE3	COMPLETED	Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
NCT03283007	PHASE3	COMPLETED	Nintedanib in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome Grade 0p-1-2
NCT03313180	PHASE3	COMPLETED	A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis
NCT03820726	PHASE3	COMPLETED	A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
NCT04093024	PHASE3	COMPLETED	A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD)
NCT05065190	PHASE3	COMPLETED	A Study to Test How Well a Medicine Called Nintedanib Helps People in China With Progressive Lung Fibrosis
NCT05067517	PHASE3	WITHDRAWN	Efficacy & Safety of Nintedanib in Patients With Progressive Fibrosing Coal Mine Dust-Induced Interstitial Lung Disease
NCT05285982	PHASE3	COMPLETED	A Study to Evaluate Long-term Safety of Nintedanib in Children and Adolescents With Interstitial Lung Disease (InPedILD®-ON)
NCT03377023	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer
NCT03805477	PHASE2	RECRUITING	Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation
NCT04976036	PHASE2	RECRUITING	Efficacy of Nintedanib for Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Patients
NCT06071013	PHASE1/PHASE2	RECRUITING	Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
NCT06643091	PHASE2	NOT_YET_RECRUITING	Nintedanib Treatment in Unicentric Castleman Disease
NCT07583589	PHASE2	NOT_YET_RECRUITING	Nintedanib With or Without Dextromethorphan in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT00706628	PHASE2	COMPLETED	A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer

Clinical evidence (CIViC)

Variant × indication × effect (1 predictive associations from 1 curated evidence items):

Variant	Indication	Effect	Therapy	Level	CIViC
CCDC6::RET Fusion	Lung Non-small Cell Carcinoma	Sensitivity/Response	Nintedanib	CIViC C	EID1601

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

245 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
Crizotinib	ChEMBL + PubChem	Phase 4 (approved)	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, LATS1, PDGFRA, PDGFRB
Fedratinib	ChEMBL + PubChem	Phase 4 (approved)	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, LATS1, PDGFRA, PDGFRB
Lenvatinib	ChEMBL + PubChem	Phase 4 (approved)	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, LATS1, PDGFRA, PDGFRB
Pazopanib	ChEMBL + PubChem	Phase 4 (approved)	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, LATS1, PDGFRA, PDGFRB
SUNITINIB	ChEMBL + PubChem	Phase 4 (approved)	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, LATS1, PDGFRA, PDGFRB
Vandetanib	ChEMBL + PubChem	Phase 4 (approved)	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, LATS1, PDGFRA, PDGFRB
DOVITINIB	ChEMBL	Phase 3	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, LATS1, PDGFRA, PDGFRB
LESTAURTINIB	ChEMBL	Phase 3	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, LATS1, PDGFRA, PDGFRB
LINIFANIB	ChEMBL	Phase 3	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, LATS1, PDGFRA, PDGFRB
SU-014813	ChEMBL	Phase 2	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, LATS1, PDGFRA, PDGFRB
TOZASERTIB	ChEMBL	Phase 2	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, LATS1, PDGFRA, PDGFRB
Afatinib	PubChem	Approved	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, LATS1, PDGFRA, PDGFRB
Selumetinib	PubChem	Approved	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, LATS1, PDGFRA, PDGFRB
Axitinib	ChEMBL + PubChem	Phase 4 (approved)	FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, LATS1, PDGFRA, PDGFRB
Gefitinib	ChEMBL + PubChem	Phase 4 (approved)	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, LATS1, PDGFRA
MIDOSTAURIN	ChEMBL + PubChem	Phase 4 (approved)	FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, LATS1, PDGFRA, PDGFRB
Ponatinib	ChEMBL + PubChem	Phase 4 (approved)	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, KDR, LATS1, PDGFRA, PDGFRB
Sorafenib	ChEMBL + PubChem	Phase 4 (approved)	FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, LATS1, PDGFRA, PDGFRB
BRIVANIB	ChEMBL	Phase 3	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB
CEDIRANIB	ChEMBL	Phase 3	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB
SEMAXANIB	ChEMBL	Phase 3	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB
OSI-632	ChEMBL	Phase 2	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB
R-406	ChEMBL	Phase 2	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB
TANDUTINIB	ChEMBL	Phase 2	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB
Idelalisib	PubChem	Approved	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, LATS1, PDGFRA, PDGFRB
INFIGRATINIB	ChEMBL	Phase 4 (approved)	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA
AT-9283	ChEMBL	Phase 2	FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, LATS1, PDGFRA
DORAMAPIMOD	ChEMBL	Phase 2	FGFR1, FGFR2, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB
FORETINIB	ChEMBL	Phase 2	FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB
REBASTINIB	ChEMBL	Phase 2	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA
Erlotinib	ChEMBL + PubChem	Phase 4 (approved)	FGFR2, FLT1, FLT4, KDR, LATS1, PDGFRA, PDGFRB
REGORAFENIB	ChEMBL + PubChem	Phase 4 (approved)	FGFR1, FLT1, FLT4, KDR, LATS1, PDGFRA, PDGFRB
Tivozanib	ChEMBL + PubChem	Phase 4 (approved)	FGFR1, FLT1, FLT4, KDR, LATS1, PDGFRA, PDGFRB
DASATINIB	ChEMBL	Phase 4 (approved)	FGFR1, FGFR2, FGFR3, FLT1, KDR, PDGFRA, PDGFRB
MOTESANIB	ChEMBL	Phase 3	FGFR1, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB
CENISERTIB	ChEMBL	Phase 2	FGFR1, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB
ILORASERTIB	ChEMBL	Phase 2	FGFR1, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB
LUCITANIB	ChEMBL	Phase 2	FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRB
MK-2461	ChEMBL	Phase 2	FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRB
Ceritinib	ChEMBL + PubChem	Phase 4 (approved)	FGFR2, FGFR3, FGFR4, KDR, LATS1, PDGFRA
Entrectinib	ChEMBL + PubChem	Phase 4 (approved)	FGFR1, FGFR3, FLT1, FLT4, KDR, LATS1
Quizartinib	ChEMBL + PubChem	Phase 4 (approved)	FLT1, FLT4, KDR, LATS1, PDGFRA, PDGFRB
BRIGATINIB	ChEMBL	Phase 4 (approved)	FGFR1, FGFR2, FGFR3, FGFR4, FLT4, KDR
RAF-265	ChEMBL	Phase 2	FGFR1, FLT1, FLT4, KDR, PDGFRA, PDGFRB
Cabozantinib	ChEMBL + PubChem	Phase 4 (approved)	FGFR1, FLT1, FLT4, KDR, LATS1
Pexidartinib	ChEMBL + PubChem	Phase 4 (approved)	FLT1, KDR, LATS1, PDGFRA, PDGFRB
ERDAFITINIB	ChEMBL	Phase 4 (approved)	FGFR1, FGFR2, FGFR3, FGFR4, KDR
FUTIBATINIB	ChEMBL	Phase 4 (approved)	FGFR1, FGFR2, FGFR3, FGFR4, KDR
ORANTINIB	ChEMBL	Phase 3	FGFR1, FLT1, KDR, LATS1, PDGFRB
VATALANIB	ChEMBL	Phase 3	FLT1, FLT4, KDR, PDGFRA, PDGFRB
CEP-11981	ChEMBL	Phase 2	FGFR1, FGFR3, FLT1, KDR, PDGFRA
DEFOSBARASERTIB	ChEMBL	Phase 2	FLT1, FLT4, KDR, PDGFRA, PDGFRB
FEXAGRATINIB	ChEMBL	Phase 2	FGFR1, FGFR2, FGFR3, FGFR4, KDR
FGFR INHIBITOR DEBIO 1347	ChEMBL	Phase 2	FGFR1, FGFR2, FGFR3, FGFR4, KDR
Imatinib	ChEMBL + PubChem	Phase 4 (approved)	KDR, LATS1, PDGFRA, PDGFRB
PEMIGATINIB	ChEMBL	Phase 4 (approved)	FGFR1, FGFR2, FGFR3, FGFR4
ALISERTIB	ChEMBL	Phase 3	FGFR1, FGFR3, FLT1, KDR
CANERTINIB	ChEMBL	Phase 3	FLT1, KDR, PDGFRA, PDGFRB
SURUFATINIB	ChEMBL	Phase 3	FGFR1, FLT1, FLT4, KDR
BFH-772	ChEMBL	Phase 2	FLT1, FLT4, KDR, PDGFRB